▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

MaxCyte (NASDAQ: MXCT)

$2.40

(3.7%)

$0.08

Price as of May 30, 2025, 3:58 p.m. ET

MaxCyte Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
MXCT	-48.82%	+46.01%	+7.35%	+46%
S&P	+12.92%	+94.19%	+14.18%	+84%

MaxCyte Company Info

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

News & Analysis

Featured Article

Why Shares of MaxCyte Are Plummeting on Thursday

The biotech company reduced full-year guidance and expects so-so third-quarter revenue.

Jim Halley | Oct 5, 2023

Valuation

Earnings Transcripts

MaxCyte, Inc. (MXCT) Q2 2022 Earnings Call Transcript

MXCT earnings call for the period ending June 30, 2022.

Motley Fool Transcribing | Aug 11, 2022

MaxCyte, Inc. (MXCT) Q1 2022 Earnings Call Transcript

MXCT earnings call for the period ending March 31, 2022.

Motley Fool Transcribing | May 10, 2022

MaxCyte, Inc. (MXCT) Q4 2021 Earnings Call Transcript

MXCT earnings call for the period ending December 31, 2021.

Motley Fool Transcribing | Mar 22, 2022

MaxCyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript

MXCT earnings call for the period ending September 30, 2021.

Motley Fool Transcribing | Nov 12, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services